Market Overview:
The global cancer angiogenesis inhibitors market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of cancer angiogenesis inhibitors. Based on type, the global cancer angiogenesis inhibitors market is segmented into VEGF targeted therapy, FGF targeted therapies, oncogene targeted therapy, matrix degrading & remodeling target therapy and others. The VEGF targeted therapy segment dominates the global market due to its high efficacy in treating various types of cancers. Based on application, the global cancer angiogenesis inhibitors market is divided into cancer and interferon alpha-2α segments. Cancer dominates the overall application segment owing to its high prevalence across all regions studied in this research study.
Product Definition:
Cancer angiogenesis inhibitors are a type of anticancer drug that blocks the development of new blood vessels in tumors. Without a steady supply of oxygen and nutrients, cancer cells cannot grow and spread. Angiogenesis inhibitors are used to treat various types of cancer, including breast cancer, colorectal cancer, renal cell carcinoma (kidney cancer), and glioblastoma (a type of brain tumor).
VEGF Targeted Therapy:
Vascular Endothelial Growth Factor (VEGF) targeted therapy, it's usage and growth factor in cancer angiogenesis inhibitors market is expected to grow at a lucrative rate during the forecast period. The factors that propel the growth of this market include increasing incidences of chronic diseases such as cancer, which are due to changing lifestyles and lack of physical activity leading to obesity. Moreover, growing demand for improved diagnostic technologies by patients & healthcare professionals further boosts the growth potential in this vertical.
FGF Targeted Therapies:
Fibroblast growth factor (FGF) targeted therapies are the drugs that act on FGF receptors. Fibroblast growth factors are a group of proteins which play an important role in wound healing and tissue repair. The main target for these drugs is the cancer cells which express high levels of fibroblast growth factor receptor (FGFR).
Application Insights:
Cancer held the largest share of the application segment in 2017. This is due to high usage of cancer-related targeted therapies and increasing incidence rates of various types of cancers. For instance, according to data published by WHO, it has been estimated that globally around 1 in 6 women and 1 in 5 men are diagnosed with some form of cancer during their lifetime. Moreover, new technologies such as VEGF targeted therapy have improved treatment outcomes for several types of cancers including melanoma, glioma, breast carcinoma and lung carcinoma.
Interferon alpha-2α (IFNalpha2) is anticipated to be the fastest growing segment owing to its rising use for multiple sclerosis treatment and availability as a generic drug across all major regions including North America & Europe/Mediterranean Sea; Asia Pacific; Latin America; Africa; Oceania (excluding Australia).
Regional Analysis:
North America dominated the global cancer angiogenesis inhibitors market in 2017. This is due to the presence of key players such as Pfizer, Inc.; Merck & Co., Inc.; and Celgene Corporation. Moreover, these companies are continuously undertaking strategic initiatives such as new product launches and expansion of distribution networks to increase revenue generation.
Growth Factors:
- Increasing incidence of cancer across the globe
- Growing awareness about cancer and its treatment options
- Rising demand for better and more effective cancer treatments
- Technological advancements in the field of cancer angiogenesis inhibitors research and development
- increasing investments by pharmaceutical companies in R&D of novel anti-cancer drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Angiogenesis Inhibitors Market Research Report
By Type
VEGF Targeted Therapy, FGF Targeted Therapies, Oncogene Targeted Therapy, Matrix Degrading & Remodeling Targeted Therapy, Others
By Application
Cancer, Interferon Alpha-2α, Ocular Neovascularization
By Companies
Intas Pharmaceuticals, Kyowa Hakko Kirin, Levolta Pharmaceuticals, Mabtech, Marsala Biotech, Neumedicines, Genentech, Five Prime Therapeutics, Fuji Film Kyowa Kirin Biologics, Genexine, Intas Pharmaceuticals, ImClone Systems, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
123
Number of Tables & Figures
87
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Angiogenesis Inhibitors Market Report Segments:
The global Cancer Angiogenesis Inhibitors market is segmented on the basis of:
Types
VEGF Targeted Therapy, FGF Targeted Therapies, Oncogene Targeted Therapy, Matrix Degrading & Remodeling Targeted Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Interferon Alpha-2α, Ocular Neovascularization
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Intas Pharmaceuticals
- Kyowa Hakko Kirin
- Levolta Pharmaceuticals
- Mabtech
- Marsala Biotech
- Neumedicines
- Genentech
- Five Prime Therapeutics
- Fuji Film Kyowa Kirin Biologics
- Genexine
- Intas Pharmaceuticals
- ImClone Systems
- Novartis
Highlights of The Cancer Angiogenesis Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- VEGF Targeted Therapy
- FGF Targeted Therapies
- Oncogene Targeted Therapy
- Matrix Degrading & Remodeling Targeted Therapy
- Others
- By Application:
- Cancer
- Interferon Alpha-2α
- Ocular Neovascularization
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Angiogenesis Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer angiogenesis inhibitors are drugs that block the growth of new blood vessels in tumors. This can slow or stop the spread of cancer cells to other parts of the body.
Some of the major companies in the cancer angiogenesis inhibitors market are Intas Pharmaceuticals, Kyowa Hakko Kirin, Levolta Pharmaceuticals, Mabtech, Marsala Biotech, Neumedicines, Genentech, Five Prime Therapeutics, Fuji Film Kyowa Kirin Biologics, Genexine, Intas Pharmaceuticals, ImClone Systems, Novartis.
The cancer angiogenesis inhibitors market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer Angiogenesis Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer Angiogenesis Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer Angiogenesis Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer Angiogenesis Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer Angiogenesis Inhibitors Market Size & Forecast, 2020-2028
4.5.1 Cancer Angiogenesis Inhibitors Market Size and Y-o-Y Growth
4.5.2 Cancer Angiogenesis Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 VEGF Targeted Therapy
5.2.2 FGF Targeted Therapies
5.2.3 Oncogene Targeted Therapy
5.2.4 Matrix Degrading & Remodeling Targeted Therapy
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Cancer
6.2.2 Interferon Alpha-2α
6.2.3 Ocular Neovascularization
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer Angiogenesis Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer Angiogenesis Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 VEGF Targeted Therapy
9.6.2 FGF Targeted Therapies
9.6.3 Oncogene Targeted Therapy
9.6.4 Matrix Degrading & Remodeling Targeted Therapy
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Cancer
9.10.2 Interferon Alpha-2α
9.10.3 Ocular Neovascularization
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 VEGF Targeted Therapy
10.6.2 FGF Targeted Therapies
10.6.3 Oncogene Targeted Therapy
10.6.4 Matrix Degrading & Remodeling Targeted Therapy
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Cancer
10.10.2 Interferon Alpha-2α
10.10.3 Ocular Neovascularization
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 VEGF Targeted Therapy
11.6.2 FGF Targeted Therapies
11.6.3 Oncogene Targeted Therapy
11.6.4 Matrix Degrading & Remodeling Targeted Therapy
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Cancer
11.10.2 Interferon Alpha-2α
11.10.3 Ocular Neovascularization
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 VEGF Targeted Therapy
12.6.2 FGF Targeted Therapies
12.6.3 Oncogene Targeted Therapy
12.6.4 Matrix Degrading & Remodeling Targeted Therapy
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Cancer
12.10.2 Interferon Alpha-2α
12.10.3 Ocular Neovascularization
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 VEGF Targeted Therapy
13.6.2 FGF Targeted Therapies
13.6.3 Oncogene Targeted Therapy
13.6.4 Matrix Degrading & Remodeling Targeted Therapy
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Cancer
13.10.2 Interferon Alpha-2α
13.10.3 Ocular Neovascularization
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer Angiogenesis Inhibitors Market: Competitive Dashboard
14.2 Global Cancer Angiogenesis Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Intas Pharmaceuticals
14.3.2 Kyowa Hakko Kirin
14.3.3 Levolta Pharmaceuticals
14.3.4 Mabtech
14.3.5 Marsala Biotech
14.3.6 Neumedicines
14.3.7 Genentech
14.3.8 Five Prime Therapeutics
14.3.9 Fuji Film Kyowa Kirin Biologics
14.3.10 Genexine
14.3.11 Intas Pharmaceuticals
14.3.12 ImClone Systems
14.3.13 Novartis
